drugset / Trial / NCT06106841
TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Phase 1/2
Terminated
19 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.
Timeline
- Start
- 2023-10-05
- Primary completion
- 2024-10-16
- Completion
- 2024-10-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB3909 | Unknown | 400 mg | — |
| Subject | TQB3909 | Unknown | 600 mg | — |